MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Gamitrinib TPP hexafluorophosphate

CAS No. : 1131626-47-5

MCE 站：Gamitrinib TPP hexafluorophosphate

产品活性：Gamitrinib TPP hexafluorophosphate 是一种 Gamitrinib (GA) 线粒体基质的抑制剂。Gamitrinib TPP hexafluorophosphate 是一种靶向线粒体的 HSP90 抑制剂。具有抗癌活性。

研究领域：Cell Cycle/DNA Damage  |  Metabolic Enzyme/Protease

作用靶点：HSP

In Vitro: Gamitrinib TPP (Gamitrinib^TPP, G-TPP), a small molecule that combines the Hsp90 ATPase inhibitory module of 17-allylamino geldanamycin (17-AAG) with the mitochondrial-targeting moiety of triphenylphosphonium. Gamitrinib TPP is selectively delivered to mitochondria ａnd does not affect Hsp90 homeostasis outside the organelle. Within a 16-hour exposure, concentrations of Gamitrinib TPP of 15-20 μM indistinguishably kill patient-derived ａnd cultured glioblastoma cell lines. This cell death response has the hallmarks of mitochondrial apoptosis, with loss of organelle inner membrane potential, release of cytochrome c in the cytosol, activation of initiator caspase-9 ａnd effector caspase-3 ａnd caspase-7, ａnd cellular reactivity for annexin V.

In Vivo: Whether the combination of TRAIL plus Gamitrinib TPP (Gamitrinib^TPP, G-TPP) has activity against glioblastoma in vivo is studied. Luciferase-expressing U87 glioblastoma cells implanted in the right cerebral striatum of immunocompromised mice give rise to rapidly growing tumors by bioluminescence imaging, ａnd treatment of these mice with vehicle, stereotactic delivery of TRAIL, or systemic administration of suboptimal concentrations of Gamitrinib TPP does not affect tumor growth in vivo. Similarly, systemic monotherapy with Gamitrinib TPP at concentrations (20 mg/kg as daily i.p. injections) that inhibit subcutaneous xenograft tumor growth in mice has no effect on orthotopic glioblastoma growth. In contrast, 2 cycles of intracranial TRAIL combined with systemic Gamitrinib TPP suppresses the growth of established glioblastomas, with no significant animal weight loss throughout treatment.

相关产品：Bioactive Compound Library Plus  |  Hsp90-IN-17  |  KNK423  |  Palmitic acid  |  HSP90-IN-18  |  Paeoniflorin  |  Pimitespib  |  Debio 0932  |  HSP90-IN-22  |  KU-177  |  AMP-PCP disodium  |  Tamoxifen  |  JG-231  |  MPC-0767  |  SNX-2112  |  HDAC6/HSP90-IN-1  |  TRC051384 hydrochloride  |  Retaspimycin  |  Onalespib  |  HM03  |  EC144  |  MAO A/HSP90-IN-1  |  2-Hexyl-4-pentynoic acid  |  Cucurbitacin D  |  Shepherdin (79-87) (TFA)  |  NCT-58  |  MKT-077  |  Cemdomespib  |  6BrCaQ-C10-TPP

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿*全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。